Metabolic Health and Diabetes Prevention Tips for Obesity

“

Abstract

In this comprehensive educational post, I walk you through a new paradigm for treating cardiometabolic diseases—conditions like obesity, type 2 diabetes, and cardiovascular disease that are deeply interconnected. We no longer view them as isolated problems but as manifestations of shared underlying dysfunctions. I will explain the physiology linking these conditions, highlighting the roles of chronic inflammation, mitochondrial dysfunction, and neurohormonal dysregulation. Drawing on the latest evidence and my clinical experience, I will illustrate our patient-centered approach through detailed case studies that show how targeting the root cause—obesity—can lead to profound improvements across the entire metabolic spectrum.

I will also explain how our unique multidisciplinary team operates. I, Dr. Alex Jimenez, coordinate integrative chiropractic and functional medicine care. This is done with the essential medical oversight of Dr. Maria Guadalupe Cardenas, MD, a Board-Certified Internist with over 40 years of experience (NPI #1164426749; Texas MD License #J2933). Dr. Cardenas serves as the Medical Director and Collaborative Physician at our practice, Injury Medical Clinic PA (also known as Mission Plaza Injury Medical Clinic) in El Paso, Texas. Together, we translate leading-edge research—including the strategic use of modern tools such as Continuous Glucose Monitors (CGMs) and pharmacotherapies such as GLP-1 receptor agonists—into personalized protocols that improve metabolic health, protect the cardiovascular system, and help patients achieve and sustain meaningful weight loss.

Our Collaborative and Integrative Approach

At Injury Medical Clinic, we believe in a team-based, patient-first model of care. My extensive training in chiropractic, functional medicine, and as a board-certified Family Nurse Practitioner allows me to view health through a unique, integrative lens. My mission is to uncover and address the root causes of dysfunction, not just manage symptoms. Our collaboration with Dr. Maria Guadalupe Cardenas, MD, powerfully supports this mission. As our Medical Director and Collaborative Physician, she provides essential medical oversight, ensuring our patients receive safe, effective, and comprehensive care that bridges conventional and functional medicine.

This kind of multidisciplinary setup is common in integrative or injury care clinics: the MD provides medical direction alongside the chiropractor, and together we build a comprehensive care pathway tailored to the patient’s clinical picture. Our team—which includes registered dietitians, behavioral health specialists, and physical/occupational therapists—integrates:

• Medical Oversight: ASCVD risk stratification, medication management, and supervision of complex comorbidities.
• Integrative Chiropractic Care: Spinal and extremity adjustments, soft-tissue therapies, and movement retraining to reduce pain and enable activity.
• Functional Medicine: Personalized nutrition, gut health restoration, and stress resilience training.
• Rehabilitation: Periodized strength and aerobic programs to build metabolic capacity.
• Personal Injury Care: Coordinated plans that address pain while preserving metabolic health during recovery.

In my practice, chiropractic care is a foundational therapy aimed at optimizing neuromusculoskeletal function. By reducing physical stressors and improving biomechanics, we create an internal environment where other treatments can work more effectively. This synergistic approach is the cornerstone of our success. My clinical observations, often shared on my HealthCoach Clinic and professional profile pages, consistently reinforce this truth: sustainable outcomes require coordinated care that addresses the whole person.

Understanding Obesity as a Chronic, Treatable Disease

I want to start by reframing obesity. In our clinic, we treat obesity as a chronic, progressive, and relapsing but highly treatable disease. This perspective is critical because it aligns the care model for obesity with those we already apply to diabetes and cardiovascular disease. Historically, this view has been slow to gain traction, with some mislabeling anti-obesity medications as vanity agents. That position conflicts with contemporary evidence recognizing obesity as a neuroendocrine, metabolic, immune, and behavioral disorder with clearly measurable pathophysiology and evidence-based treatments (Bray et al., 2017; Apovian et al., 2015).

Key takeaways:

• Obesity has identifiable biological drivers beyond willpower.
• Treating obesity early changes the trajectory of dyslipidemia, hypertension, and insulin resistance.
• Long-term management requires the same seriousness we give to diabetes and atherosclerotic cardiovascular disease (ASCVD).

The Physiology: Why Body Weight Is Tightly Regulated

The human body tightly regulates critical variables like temperature and blood volume. Body weight is also tightly regulated by a complex network involving the hypothalamus, brainstem, vagal nerves, adipose-derived hormones (such as leptin), and gut peptides (such as GLP-1) (Morton et al., 2014). When this network is disrupted, the “settling point” for body weight drifts upward—appetite signaling increases, satiety signaling decreases, and energy expenditure falls.

This is what I mean when I tell patients: overeating does not simply cause obesity—obesity biology can cause overeating by amplifying hunger hormones and blunting satiety cues.

• The “first hit” is often neurohormonal dysregulation. This includes elevated ghrelin (the “hunger hormone”) and reduced leptin sensitivity (leptin signals fullness), as well as altered signaling of gut hormones such as GLP-1 and PYY (Blüher, 2019).
• The “second hit” is the brain defending this new, higher fat-mass set point. When a person loses weight, adaptive thermogenesis lowers their resting energy expenditure and intensifies hunger. This is tied to hypothalamic inflammation and gliosis (scarring) observed in both animal models and human imaging (Thaler et al., 2012; Sumithran et al., 2011).

This is biology, not a character flaw. Recognizing this helps patients shift from shame to strategy—and informs why we use targeted treatments like GLP-1 receptor agonists that act directly on these dysregulated pathways.

The Overlap: How Obesity, Diabetes, and Cardiovascular Disease Intersect

Three shared pillars bind these conditions together, creating a vicious cycle:

1. Chronic Inflammation and Immunometabolic Activation: In central obesity, enlarged fat cells and infiltrating immune cells release inflammatory cytokines (e.g., TNF-?, IL-6) that impair insulin signaling system-wide.
2. Insulin Resistance and Lipotoxicity: When cells become resistant to insulin, the pancreas works harder, eventually leading to beta-cell stress and failure. Excess fat is stored in non-adipose tissues, such as the liver and muscle (lipotoxicity), further worsening metabolic function.
3. Mitochondrial Dysfunction and Oxidative Stress: Impaired mitochondrial function leads to less efficient energy production and increased reactive oxygen species (ROS), which damage cellular components, including those involved in insulin signaling and vascular health.

A key mediator in this triad is nitric oxide (NO). Under healthy conditions, NO promotes vasodilation, inhibits platelet aggregation, and improves glucose handling. In cardiometabolic disease, oxidative stress scavenges NO, leading to endothelial dysfunction—the first step toward atherosclerosis (González et al., 2020). This is why treating obesity early is so profoundly cardioprotective. A sustained 5–15% weight reduction yields graded benefits across A1C, triglycerides, blood pressure, and quality of life (Jensen et al., 2014).

Case Study: Victoria’s Journey Through Menopause, Diabetes, and Weight Gain

To bring this to life, I’d like to introduce Victoria, a 52-year-old IT professional whose journey resonates with so many women. She came to me for a follow-up on her prediabetes, distressed by a 15-pound weight gain over the past year despite her best efforts.

Victoria’s Initial Profile:

• Age: 52, postmenopausal
• Symptoms: Waking at night with sweats and racing thoughts, daily hot flashes, snoring, and high stress.
• Physical Exam: Weight 185 lbs (BMI of 31.8, Class 1 Obesity) with a central pattern of fat distribution.

Victoria’s case is a powerful illustration of the metabolic shifts that occur during the menopausal transition. The decline in estradiol is linked to increased insulin resistance, a tendency to gain abdominal fat, unfavorable changes in cholesterol levels, and loss of muscle mass. Her lab results confirmed these trends: her A1C had risen to 7.3%, officially diagnosing her with type 2 diabetes, and her HOMA-IR score of 4.7 confirmed significant insulin resistance.

Instead of overwhelming her, I asked: “What area would you like to target first?”

Victoria chose to focus on her medication and understanding her body’s response to food. We increased her metformin, and she agreed to try a Continuous Glucose Monitor (CGM) for 14 days. The CGM data was transformative. It provides a 24/7 view of glucose levels, revealing how specific foods, stress, and activity affect blood sugar in real time. Seeing her glucose spike after certain meals was far more impactful than a static A1C value. It motivated her to increase protein and eliminate sugary drinks.

Despite these changes and starting menopause hormone therapy (MHT) for her hot flashes, her weight loss was minimal. This is where we combined therapies. Research shows that adding a GLP-1 receptor agonist, such as semaglutide, to MHT leads to greater weight reduction. Victoria agreed to start this therapy.

At this stage, integrative chiropractic care became a crucial supportive element. Her sedentary job and central adiposity were causing poor posture and musculoskeletal strain. Regular chiropractic adjustments helped to:

• Improve spinal alignment and mobility to reduce physical stress.
• Enhance nervous system function to help modulate her stress response.
• Alleviate biomechanical discomfort to make it easier for her to increase her physical activity.

One year later, the results were remarkable. Victoria’s weight dropped to 160 pounds (BMI down to 27.5). Her A1C, insulin, and cholesterol all normalized. By treating her obesity comprehensively, we successfully reversed her diabetes and significantly reduced her future cardiovascular risk.

Case Study: Stephen’s Path From Prediabetes to Metabolic Health

Another powerful example is Stephen, a 24-year-old with prediabetes, a BMI of 32.1, and a strong family history of cardiometabolic disease. He wanted a plan to prevent progression to diabetes. I explained that while a 3% weight loss could help, more substantial improvements often require 10–15% total body weight loss (TWL) or more.

After discussing options, Stephen elected to start tirzepatide, a dual GLP-1/GIP agonist, which we titrated slowly to ensure tolerability. In parallel, we set lifestyle targets:

• Nutrition: Replace sugary drinks, prioritize lean protein and fiber.
• Activity: Build daily steps and start resistance training twice a week.
• Behavioral: Implement a regular sleep schedule and daily breathwork.
• Chiropractic and Movement Care: I identified thoracolumbar stiffness and hip flexor tightness. We scheduled regular adjustments and corrective exercises to improve his gait mechanics and reduce lower-back strain.

At one year, Stephen had lost 50 pounds—roughly 20% TWL. His HbA1c dropped to 5.4% (normal), and his lipid panel normalized. The chiropractic care was pivotal; by restoring joint mechanics and optimizing movement patterns, we enabled him to tolerate higher activity volumes without pain, which was critical for his adherence and cumulative energy expenditure.

The Four Pillars of Our Integrated Treatment Model

Our approach is structured around four pillars, with medical oversight from Dr. Cardenas and integrative support from our team.

1. Nutrition and Metabolic Recalibration

We focus on sustainable, personalized plans. Strategies include a modest caloric reduction, increased protein intake to preserve muscle and enhance satiety, and an emphasis on high-fiber, minimally processed foods. The best plan is one a patient can adhere to over the long term.

2. Physical Activity, Rehab, and Chiropractic Care

Exercise is not just “burning calories”; it is a mitochondrial and endothelial therapy. It increases NO bioavailability, enhances insulin sensitivity, and stimulates mitochondrial biogenesis. Our approach includes:

• Progressive Resistance Training: To build and preserve lean mass, which is crucial for maintaining resting metabolic rate during weight loss.
• Zone 2 Aerobic Work: To enhance mitochondrial density and fat oxidation.
• Integrative Chiropractic Care: To restore joint mechanics, reduce pain, and improve movement confidence. My clinical observations show that patients receiving regular chiropractic care alongside rehab demonstrate better activity consistency and adherence. By reducing nociceptive input (pain signals) and improving autonomic balance, we unlock a patient’s capacity to train effectively.

3. Behavioral Health, Sleep, and Stress Care

We screen for and address factors like anxiety, depression, sleep apnea, and insomnia. Optimizing sleep and implementing stress-reduction techniques like breathwork are non-negotiable, as they directly affect insulin sensitivity and appetite-regulating hormones such as ghrelin and leptin.

4. Evidence-Based Medical Management

Modern anti-obesity and diabetes medications are biology-aligned tools. Under Dr. Cardenas’s medical direction, we strategically use:

• Incretin-Based Therapies: GLP-1 receptor agonists (e.g., semaglutide, liraglutide) and dual GLP-1/GIP agonists (e.g., tirzepatide) are highly effective. They reduce appetite, improve satiety, and have demonstrated cardiovascular benefits in at-risk populations (Wilding et al., 2021; Jastreboff et al., 2022).
• SGLT2 Inhibitors: These medications improve heart failure and renal outcomes while modestly reducing weight (Zinman et al., 2015).
• Strategic Medication Selection: We actively avoid or substitute medications known to promote weight gain (e.g., certain beta-blockers, sulfonylureas) whenever clinically appropriate, a process overseen by Dr. Cardenas.

It is crucial to understand that stopping these therapies often leads to rapid weight regain and reversal of metabolic benefits, underscoring the chronic nature of obesity (Rubino et al., 2021).

---

Chiropractic Care & Metabolism *The Hidden Link*- Video

---

Putting It All Together: A Stepwise, Personalized Approach

When a new patient comes to our clinic, the process is clear and collaborative:

1. Clarify Goals and Barriers: We conduct a comprehensive intake covering medical history, lifestyle, pain points, and medications.
2. Establish a Baseline: We gather metrics like body composition, A1C, lipids, hs-CRP, blood pressure, and functional movement screens. In some cases, we screen for liver disease with a FIB-4 score, a non-invasive calculator that can indicate risk for advanced liver fibrosis.
3. Initiate a High-Impact Foundation: We start with foundational changes in nutrition, sleep, stress modulation, and movement.
4. Integrate Chiropractic, Rehab, and Pharmacotherapy: We address biomechanical barriers with chiropractic care and rehabilitative exercise. When indicated, Dr. Cardenas initiates and manages pharmacotherapy to target appetite biology and cardiometabolic risk.
5. Monitor, Iterate, and Maintain: We have regular 4–12 week checkpoints to track progress, adjust the plan, and build relapse-prevention skills for long-term success.

Final Thoughts: Treat Obesity to Treat Cardiometabolic Disease

Treating obesity as a chronic disease with long-term, evidence-based tools is not optional—it is central to preventing diabetes progression and reducing cardiovascular events. When we integrate the medical oversight of an experienced internist like Dr. Cardenas with the hands-on, functional approach of integrative chiropractic care, rehabilitation, and functional medicine, patients experience fewer barriers, better adherence, and more durable, life-changing outcomes. That is the heart of our work at Injury Medical Clinic PA in El Paso, Texas. If you are navigating these complex health challenges, know that your biology is adaptable—and with the right, comprehensive plan, you can change your trajectory.

References

• American College of Sports Medicine. (2022). ACSM’s Guidelines for Exercise Testing and Prescription (11th ed.). journals.lww.com/acsm-essr/pages/default.aspx
• American Diabetes Association. (2024). Standards of medical care in diabetes—2024. Diabetes Care. diabetesjournals.org/care
• Apovian, C. M., Aronne, L. J., Bessesen, D. H., et al. (2015). Pharmacological management of obesity: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism.
• Arnett, D. K., Blumenthal, R. S., Albert, M. A., et al. (2019). 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. Circulation.
• Blüher, M. (2019). Obesity: Global epidemiology and pathogenesis. Nature Reviews Endocrinology.
• Bray, G. A., Kim, K. K., Wilding, J. P. H. (2017). Obesity: A chronic relapsing progressive disease process. Obesity Reviews.
• Cani, P. D. (2018). Human gut microbiome: Hype or hope for cardiometabolic disease? Journal of Clinical Investigation.
• Davies, M. J., et al. (2023). Effect of once-weekly semaglutide vs placebo on diabetes incidence in adults with overweight or obesity and prediabetes. Diabetes Care. diabetesjournals.org/care/article/46/3/607/148384/Effect-of-Once-Weekly-Semaglutide-vs-Placebo-on
• DeFronzo, R. A., Ferrannini, E., Groop, L., et al. (2015). Type 2 diabetes mellitus. Nature Reviews Disease Primers.
• DeFronzo, R. A. (2009). From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. diabetesjournals.org/care/article/32/2/176/24786/From-the-Triumvirate-to-the-Ominous-Octet-A-New
• Depner, C. M., Stothard, E. R., Wright, K. P. (2019). Metabolic consequences of sleep and circadian disorders. Current Diabetes Reports.
• Donath, M. Y., & Shoelson, S. E. (2011). Type 2 diabetes as an inflammatory disease. Nature Reviews Immunology.
• DPP Research Group. (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine. doi.org/10.1056/NEJMoa012512
• Eckel, R. H., Jakicic, J. M., Ard, J. D., et al. (2014). 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults. Circulation.
• ElSayed, N. A., et al. (2025). 1. Improving Care and Promoting Health in Populations: Standards of Care in Diabetes—2025. Diabetes Care, 48(Supplement_1), S1–S4. diabetesjournals.org/care/article/48/Supplement_1/S1/153956/1-Improving-Care-and-Promoting-Health-in
• Estruch, R., et al. (2018). Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. New England Journal of Medicine. www.nejm.org/doi/full/10.1056/NEJMoa1800389
• Garvey, W. T., Mechanick, J. I., Brett, E. M., et al. (2016). American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocrine Practice.
• Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., et al. (2019). Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND). The Lancet.
• González, D., Álvarez-García, V., Calle, C., & Martín, V. (2020). Nitric oxide and its metabolic effects. Nutrients.
• Hall, K. D., Ayuketah, A., Brychta, R., et al. (2019). Ultra-processed diets cause excess calorie intake and weight gain. Cell Metabolism.
• Hawley, J. A., & Lessard, S. J. (2008). Exercise training-induced improvements in insulin action. Journal of Applied Physiology. journals.physiology.org/doi/full/10.1152/japplphysiol.90880.2008
• Heindel, J. J., Blumberg, B. (2019). Environmental obesogens: Mechanisms and controversies. Annual Review of Pharmacology and Toxicology.
• Holloszy, J. O. (2011). Regulation by exercise of skeletal muscle content of mitochondria and GLUT4. Journal of Physiology.
• Holman, R. R., Paul, S. K., Bethel, M. A., et al. (2008). 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine.
• Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine.
• Jensen, M. D., Ryan, D. H., Apovian, C. M., et al. (2014). AHA/ACC/TOS guideline for the management of overweight and obesity in adults. Circulation.
• Libby, P., Buring, J. E., Badimon, L., et al. (2019). Atherosclerosis. Nature Reviews Disease Primers.
• Locke, A. E., Kahali, B., Berndt, S. I., et al. (2015). Genetic studies of body mass index yield new insights for obesity biology. Nature.
• Look AHEAD Research Group. (2013). Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. New England Journal of Medicine. doi.org/10.1056/NEJMoa1212914
• Marso, S. P., Daniels, G. H., Brown-Frandsen, K., et al. (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). New England Journal of Medicine.
• Marso, S. P., Bain, S. C., Consoli, A., et al. (2016b). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). New England Journal of Medicine.
• Morton, G. J., Meek, T. H., & Schwartz, M. W. (2014). Neurobiology of food intake in health and disease. Nature Reviews Neuroscience.
• Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2015). Anti-obesity drug discovery. EMBO Molecular Medicine.
• Patti, M. E., Corvera, S. (2010). The role of mitochondria in the pathogenesis of type 2 diabetes. Endocrine Reviews.
• Perkovic, V., Jardine, M. J., Neal, B., et al. (2019). Canagliflozin and renal outcomes. New England Journal of Medicine.
• Rubino, D. M., Greenway, F. L., Khalid, U., et al. (2021). Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes, Obesity and Metabolism.
• Spiegel, K., et al. (2004). Brief communication: Sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite. Annals of Internal Medicine. www.annals.org/aim/fullarticle/717090/sleep-curtailment-physiological-consequences
• Sumithran, P., Prendergast, L. A., Delbridge, E., et al. (2011). Long-term persistence of hormonal adaptations to weight loss. New England Journal of Medicine.
• Thaler, J. P., Yi, C.-X., Schur, E. A., et al. (2012). Obesity is associated with hypothalamic injury in rodents and humans. Journal of Clinical Investigation.
• Virani, S. S., Alonso, A., Benjamin, E. J., et al. (2020). Heart disease and stroke statistics—2020 update. Circulation.
• Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine.
• Wiviott, S. D., Raz, I., Bonaca, M. P., et al. (2019). Dapagliflozin and cardiovascular outcomes. New England Journal of Medicine.
• Zinman, B., Wanner, C., Lachin, J. M., et al. (2015). Empagliflozin and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine.

SEO tags: obesity treatment, cardiometabolic health, integrative chiropractic care, Dr. Alex Jimenez, Dr. Maria Guadalupe Cardenas, GLP-1 receptor agonists, tirzepatide, semaglutide, SGLT2 inhibitors, nitric oxide, hypothalamic inflammation, autonomic balance, functional medicine, weight regain, metabolic adaptation, Injury Medical Clinic PA, El Paso chiropractor, multidisciplinary obesity clinic, internal medicine collaboration, personal injury rehabilitation, type 2 diabetes, continuous glucose monitor, CGM, metabolic health, menopause, insulin resistance, cardiovascular risk, FIB-4, MASLD, holistic health, prediabetes treatment, resistance training insulin sensitivity, sleep stress metabolic health, dietitian obesity program